Lei, W.-T.; Lin, C.-Y.; Chu, S.-H.; Fang, L.-C.; Kao, Y.-H.; Tsai, P.-L.; Lin, Y.-W.; Sung, F.-C.; Wu, S.-I.
The Impact of Montelukast Duration on the Risk of Neuropsychiatric Disorders in Children with Asthma: A Population-Based Cohort Study. Pharmaceuticals 2025, 18, 379.
https://doi.org/10.3390/ph18030379
AMA Style
Lei W-T, Lin C-Y, Chu S-H, Fang L-C, Kao Y-H, Tsai P-L, Lin Y-W, Sung F-C, Wu S-I.
The Impact of Montelukast Duration on the Risk of Neuropsychiatric Disorders in Children with Asthma: A Population-Based Cohort Study. Pharmaceuticals. 2025; 18(3):379.
https://doi.org/10.3390/ph18030379
Chicago/Turabian Style
Lei, Wei-Te, Chien-Yu Lin, Szu-Hung Chu, Li-Ching Fang, Yu-Hsuan Kao, Po-Li Tsai, Yu-Wen Lin, Fung-Chang Sung, and Shu-I Wu.
2025. "The Impact of Montelukast Duration on the Risk of Neuropsychiatric Disorders in Children with Asthma: A Population-Based Cohort Study" Pharmaceuticals 18, no. 3: 379.
https://doi.org/10.3390/ph18030379
APA Style
Lei, W.-T., Lin, C.-Y., Chu, S.-H., Fang, L.-C., Kao, Y.-H., Tsai, P.-L., Lin, Y.-W., Sung, F.-C., & Wu, S.-I.
(2025). The Impact of Montelukast Duration on the Risk of Neuropsychiatric Disorders in Children with Asthma: A Population-Based Cohort Study. Pharmaceuticals, 18(3), 379.
https://doi.org/10.3390/ph18030379